Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

BACKGROUND: Metastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with promising anticancer activities. This multicenter, randomized, double-blinded,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Rui-Hua, Shen, Lin, Wang, Ke-Ming, Wu, Gang, Shi, Chun-Mei, Ding, Ke-Feng, Lin, Li-Zhu, Wang, Jin-Wan, Xiong, Jian-Ping, Wu, Chang-Ping, Li, Jin, Liu, Yun-Peng, Wang, Dong, Ba, Yi, Feng, Jue-Ping, Bai, Yu-Xian, Bi, Jing-Wang, Ma, Li-Wen, Lei, Jian, Yang, Qing, Yu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741870/
https://www.ncbi.nlm.nih.gov/pubmed/29273089
http://dx.doi.org/10.1186/s40880-017-0263-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741870/
https://www.ncbi.nlm.nih.gov/pubmed/29273089
http://dx.doi.org/10.1186/s40880-017-0263-y

Ejemplares similares